Get started
Author

Rami M. Shaker

Observed names: Rami Shaker, Shaker, Rami M.
ORCID: 0000-0002-5394-1563
Observed ORCID: 0000-0002-5394-1563
OpenAlex ID: A5078231293
Stereoselective Dynamic Cyclization of Allylic Azides: Synthesis of Tetralins, Chromanes, and Tetrahydroquinolines
2018 · Matthew R. Porter, Rami M. Shaker, et al. · Journal of the American Chemical Society · 53
Machine learning model development for quantitative analysis of CT heterogeneity in canine hepatic masses may predict histologic malignancy
2021 · Rami Shaker, Christopher Wilke, et al. · Veterinary Radiology & Ultrasound · 18
Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
2023 · Justin Hwang, Xiaolei Shi, et al. · Clinical Cancer Research · 15
PDF
Patient Outcomes and Unit Composition With Transition to a High-Intensity ICU Staffing Model: A Before-and-After Study
2023 · Jennifer L. Proper, David A. Wacker, et al. · Critical Care Explorations · 3
Supplementary Figure 3 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
2025 · Justin Hwang, Xiaolei Shi, et al.
Supplementary Table 2 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
2025 · Justin Hwang, Xiaolei Shi, et al.
Supplementary Figure 2 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
2025 · Justin Hwang, Xiaolei Shi, et al.
Supplementary Figure 1 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
2025 · Justin Hwang, Xiaolei Shi, et al.
Supplementary Table 1 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
2025 · Justin Hwang, Xiaolei Shi, et al.
Supplementary Table 3 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
2025 · Justin Hwang, Xiaolei Shi, et al.
Supplementary Table 2 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
2024 · Justin Hwang, Xiaolei Shi, et al.
Supplementary Figure 1 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
2024 · Justin Hwang, Xiaolei Shi, et al.
Supplementary Table 1 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
2024 · Justin Hwang, Xiaolei Shi, et al.
Supplementary Table 3 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
2024 · Justin Hwang, Xiaolei Shi, et al.
Data from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
2024 · Justin Hwang, Xiaolei Shi, et al.
Supplementary Figure 3 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
2024 · Justin Hwang, Xiaolei Shi, et al.
Supplementary Table 1 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
2024 · Justin Hwang, Xiaolei Shi, et al.
Supplementary Table 3 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
2024 · Justin Hwang, Xiaolei Shi, et al.
Supplementary Figure 2 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
2024 · Justin Hwang, Xiaolei Shi, et al.
Supplementary Table 2 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
2024 · Justin Hwang, Xiaolei Shi, et al.
Supplementary Figure 1 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
2024 · Justin Hwang, Xiaolei Shi, et al.
Supplementary Figure 3 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
2024 · Justin Hwang, Xiaolei Shi, et al.
Supplementary Figure 2 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
2024 · Justin Hwang, Xiaolei Shi, et al.
Assessing Sarcoma Awareness Among the General Population in Minnesota: A Cross-Sectional Survey Study from the Minnesota State Fair in 2015 and 2022
2024 · Nea Fride, Kristine M. Nachbor, et al. · Journal of Cancer Education
Supplementary Table 1 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
2023 · Justin Hwang, Xiaolei Shi, et al.
Works count: 52
Citation count: 89
H-index: 3
I10-index: 3
Year
Topic
Type